Protean Biodiagnostics

Authors: R Khalife, A Magliocco, A Gholami, S Krishna, T Love, H Sorensen, L Sucheston-Campbell Journal: Journal of Molecular Diagnostics | Volume 25, Issue 11 Publisher: Elsevier Science Inc

Protean’s abstract was accepted for presentation at the upcoming American Association for Cancer Research (AACR) Virtual Annual Meeting.

Breast cancer screening tests, including mammograms, ultrasounds, and MRIs, were delayed as a result of the COVID-19 pandemic, according to studies presented at the American Association of Cancer Research Virtual Meeting: COVID-19 and Cancer.

Last week, the Protean team was represented among companies in Orlando’s medical city.

Dr. Magliocco is a board-certified Pathologist and Professor of Oncology and Pathology with over 30 of years of experience in tissue pathology, medical research, molecular diagnostics, liquid biopsy, genetics, digital image analysis and clinical trials.

Protean BioDiagnostic’s services and vision are driven by a team. The company is committed to making quality cancer testing available to all cancer patients.

Protean BioDiagnostics is committed to creating and deploying the latest and highest quality laboratory diagnostic tools to support physicians committed to providing the best possible care for their patients regardless of where they live.

The company accepts inquiries by form, email, or phone and generally responds within one business day.